{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:37:03Z","timestamp":1770651423816,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1136\/ard.2004.023572","type":"journal-article","created":{"date-parts":[[2004,9,3]],"date-time":"2004-09-03T00:12:55Z","timestamp":1094170375000},"page":"449-456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis"],"prefix":"10.1016","volume":"64","author":[{"given":"L S","family":"Lohmander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"McKeith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Malmen\u00e4s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Bolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Kalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Genti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Szechinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Ramos-Remus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2004.023572_bib1","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P","article-title":"Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology subcommittee on osteoarthritis guidelines","volume":"43","author":"ACR","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.023572_bib2","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/ard.59.12.936","article-title":"EULAR recommendations for the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT)","volume":"59","author":"Pendleton","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.023572_bib3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1053\/gast.2001.21907","article-title":"Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient","volume":"120","author":"Laine","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1136\/ard.2004.023572_bib4","first-page":"18","article-title":"Epidemiology of NSAID induced gastrointestinal complications","volume":"26","author":"Singh","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.023572_bib5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0016-5085(89)80061-7","article-title":"Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use","volume":"96","author":"Fries","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1136\/ard.2004.023572_bib6","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/gast.2000.16510","article-title":"NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2","volume":"119","author":"Wallace","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1136\/ard.2004.023572_bib7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0149-2918(00)88318-6","article-title":"Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers","volume":"21","author":"Agrawal","year":"1999","journal-title":"Clin Ther"},{"key":"10.1136\/ard.2004.023572_bib8","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1001\/jama.282.20.1921","article-title":"Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial","volume":"282","author":"Simon","year":"1999","journal-title":"JAMA"},{"key":"10.1136\/ard.2004.023572_bib9","first-page":"530","article-title":"Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis","volume":"51","author":"Kivitz","year":"2002","journal-title":"J Fam Pract"},{"key":"10.1136\/ard.2004.023572_bib10","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1053\/gast.1997.v112.pm9178671","article-title":"Famotidine for healing and maintenance in nonsteroidal anti- inflammatory drug-associated gastroduodenal ulceration","volume":"112","author":"Hudson","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1136\/ard.2004.023572_bib11","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(99)02332-6","article-title":"Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison","volume":"354","author":"Emery","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ard.2004.023572_bib12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D","article-title":"Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo controlled trial","volume":"43","author":"Hawkey","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.023572_bib13","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0016-5085(99)70334-3","article-title":"A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group","volume":"117","author":"Laine","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1136\/ard.2004.023572_bib14","first-page":"S23","article-title":"NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials? The gastroenterologist's perspective","volume":"19","author":"Hawkey","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2004.023572_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0002-9343(97)00207-6","article-title":"Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury","volume":"104","author":"Griffin","year":"1998","journal-title":"Am J Med"},{"key":"10.1136\/ard.2004.023572_bib16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/gut.52.4.600","article-title":"Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors","volume":"52","author":"Hawkey","year":"2003","journal-title":"Gut"},{"key":"10.1136\/ard.2004.023572_bib17","author":"Office of Population Censuses and Surveys","year":"1995","journal-title":"Mortality statistics: cause. Review of the Registrar General on deaths by cause, sex and age in England and Wales, 1993"},{"key":"10.1136\/ard.2004.023572_bib18","first-page":"346","article-title":"Cooperative modulation of gastrointestinal mucosal defence by prostaglandins and nitric oxide","volume":"19","author":"Wallace","year":"1996","journal-title":"Clin Invest Med"},{"key":"10.1136\/ard.2004.023572_bib19","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJM200009213431202","article-title":"Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding","volume":"343","author":"Lanas","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2004.023572_bib20","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2165\/00002018-200124110-00002","article-title":"Nitric oxide-releasing NSAIDs. A review of their current status","volume":"24","author":"Fiorucci","year":"2001","journal-title":"Drug Saf"},{"key":"10.1136\/ard.2004.023572_bib21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejps.2003.10.020","article-title":"A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate","volume":"21","author":"Berndt","year":"2004","journal-title":"Eur J Pharm Sci"},{"issue":"Suppl","key":"10.1136\/ard.2004.023572_bib22","first-page":"S77","article-title":"The CINOD AZD3582 inhibits cyclooxygenase and reduces pain, inflammation and fever in the rat","volume":"17","author":"Berge","year":"2002","journal-title":"Eur J Pharm Sci"},{"issue":"Suppl 1","key":"10.1136\/ard.2004.023572_bib23","first-page":"286","article-title":"AZD3582 reduces pain, inflammation and fever in animals","volume":"61","author":"Berge","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.023572_bib24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2036.1997.115286000.x","article-title":"NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects,","volume":"11","author":"Davies","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1136\/ard.2004.023572_bib25","doi-asserted-by":"crossref","first-page":"PL235","DOI":"10.1016\/S0024-3205(98)00072-1","article-title":"Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat","volume":"62","author":"Muscara","year":"1998","journal-title":"Life Sci"},{"issue":"Suppl 1","key":"10.1136\/ard.2004.023572_bib26","first-page":"288","article-title":"AZD3582, a COX-inhibiting nitric oxide donator (CINOD), is gastroprotective in the rat","volume":"61","author":"\u00d6jteg","year":"2002","journal-title":"Ann Rhuem Dis"},{"key":"10.1136\/ard.2004.023572_bib27","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/gut.52.11.1537","article-title":"Gastrointestinal safety of AZD3582: a cyclooxygenase inhibiting nitric oxide donator: proof of concept in humans","volume":"52","author":"Hawkey","year":"2003","journal-title":"Gut"},{"key":"10.1136\/ard.2004.023572_bib28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1046\/j.1365-2036.1999.00529.x","article-title":"Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen","volume":"13","author":"Lanza","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1136\/ard.2004.023572_bib29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01535722","article-title":"GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease","volume":"33","author":"Svedlund","year":"1988","journal-title":"Dig Dis Sci"},{"key":"10.1136\/ard.2004.023572_bib30","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.023572_bib31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"Suppl 1","key":"10.1136\/ard.2004.023572_bib32","first-page":"269","article-title":"A common pathway for nitric oxide release from AZD3582 and glyceryl trinitrate","volume":"61","author":"Berndt","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.023572_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.1365-2036.2003.01407.x","article-title":"Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib","volume":"17","author":"Hunt","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1136\/ard.2004.023572_bib34","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1572-0241.2001.03740.x","article-title":"Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis","volume":"96","author":"Goldstein","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1136\/ard.2004.023572_bib35","unstructured":"Vioxx. Rofecoxib tablets and oral suspension. Prescribing information. Whitehouse Station, New Jersey: Merck and Co, 1999."},{"key":"10.1136\/ard.2004.023572_bib36","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1046\/j.1365-2036.2001.01007.x","article-title":"Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials","volume":"15","author":"Hawkey","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1136\/ard.2004.023572_bib37","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1007\/BF01540567","article-title":"Endoscopic comparison of cimetidine and sucralfate for prevention of naproxen-induced acute gastroduodenal injury. Effect of scoring method","volume":"35","author":"Lanza","year":"1990","journal-title":"Dig Dis Sci"},{"key":"10.1136\/ard.2004.023572_bib38","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3109\/00365529709000182","article-title":"A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen","volume":"32","author":"Bjarnason","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1136\/ard.2004.023572_bib39","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1111\/j.1572-0241.2001.03932.x","article-title":"Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments","volume":"96","author":"Talley","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1136\/ard.2004.023572_bib40","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1046\/j.1365-2036.1998.00410.x","article-title":"Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies)","volume":"12","author":"Talley","year":"1998","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724430902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724430902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2004.023572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:26:54Z","timestamp":1736141214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724430902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0003496724430902"],"URL":"https:\/\/doi.org\/10.1136\/ard.2004.023572","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2004.023572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Copyright 2005 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}